Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.26
MNK's Cash to Debt is ranked lower than
69% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.03 vs. MNK: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
MNK' s 10-Year Cash to Debt Range
Min: 0.15   Max: N/A
Current: 0.26

Equity to Asset 0.41
MNK's Equity to Asset is ranked lower than
53% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.43 vs. MNK: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
MNK' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.41
Current: 0.41

0.25
0.41
Z-Score: 1.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4.30
MNK's Operating margin (%) is ranked lower than
60% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. MNK: -4.30 )
Ranked among companies with meaningful Operating margin (%) only.
MNK' s 10-Year Operating margin (%) Range
Min: -11.18   Max: 11.91
Current: -4.3

-11.18
11.91
Net-margin (%) -5.75
MNK's Net-margin (%) is ranked lower than
60% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. MNK: -5.75 )
Ranked among companies with meaningful Net-margin (%) only.
MNK' s 10-Year Net-margin (%) Range
Min: -12.57   Max: 7.45
Current: -5.75

-12.57
7.45
ROE (%) -5.17
MNK's ROE (%) is ranked lower than
59% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.48 vs. MNK: -5.17 )
Ranked among companies with meaningful ROE (%) only.
MNK' s 10-Year ROE (%) Range
Min: -10.28   Max: 9.37
Current: -5.17

-10.28
9.37
ROA (%) -1.88
MNK's ROA (%) is ranked lower than
59% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. MNK: -1.88 )
Ranked among companies with meaningful ROA (%) only.
MNK' s 10-Year ROA (%) Range
Min: -3.89   Max: 3.31
Current: -1.88

-3.89
3.31
ROC (Joel Greenblatt) (%) -9.18
MNK's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.04 vs. MNK: -9.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19.35   Max: 19.2
Current: -9.18

-19.35
19.2
» MNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MNK Guru Trades in Q2 2014

Richard Perry 134,322 sh (New)
Mario Gabelli 2,656 sh (New)
Chase Coleman 729,373 sh (New)
Paul Singer 916,000 sh (New)
Jana Partners 5,725,711 sh (+75.22%)
John Paulson 6,724,800 sh (+19.30%)
John Paulson 6,724,800 sh (+19.30%)
First Eagle Investment 187 sh (unchged)
Chuck Royce Sold Out
Pioneer Investments 120,663 sh (-0.68%)
Jim Simons 238,900 sh (-5.98%)
Paul Tudor Jones 308,900 sh (-14.22%)
» More
Q3 2014

MNK Guru Trades in Q3 2014

Steven Cohen 31,900 sh (New)
Chuck Royce 23,407 sh (New)
Joel Greenblatt 115,541 sh (New)
John Hussman 67,275 sh (New)
Richard Perry 1,150,000 sh (+756.15%)
Mario Gabelli 7,134 sh (+168.60%)
Jim Simons 359,502 sh (+50.48%)
John Paulson 9,000,000 sh (+33.83%)
Pioneer Investments 120,582 sh (unchged)
First Eagle Investment 187 sh (unchged)
Paul Singer Sold Out
Jana Partners Sold Out
Chase Coleman Sold Out
Paul Tudor Jones 24,849 sh (-91.96%)
» More
Q4 2014

MNK Guru Trades in Q4 2014

Louis Moore Bacon 14,363 sh (New)
RS Investment Management 34,500 sh (New)
Pioneer Investments 1,418,356 sh (+1076.26%)
Mario Gabelli 7,922 sh (+11.05%)
John Paulson 9,012,293 sh (+0.14%)
John Hussman 67,275 sh (unchged)
First Eagle Investment 187 sh (unchged)
Richard Perry Sold Out
Chuck Royce Sold Out
Steven Cohen 31,700 sh (-0.63%)
Joel Greenblatt 110,019 sh (-4.78%)
Jim Simons 117,502 sh (-67.32%)
Paul Tudor Jones 2,184 sh (-91.21%)
» More
Q1 2015

MNK Guru Trades in Q1 2015

Jeremy Grantham 2,200 sh (New)
Andreas Halvorsen 3,537,330 sh (New)
Paul Tudor Jones 28,384 sh (+1199.63%)
Pioneer Investments 1,454,418 sh (+2.54%)
RS Investment Management 34,500 sh (unchged)
First Eagle Investment 187 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
John Paulson 8,460,293 sh (-6.12%)
Mario Gabelli 7,122 sh (-10.10%)
Louis Moore Bacon 10,401 sh (-27.58%)
Joel Greenblatt 64,775 sh (-41.12%)
John Hussman 25,000 sh (-62.84%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 26.60
MNK's Forward P/E is ranked higher than
65% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 129.87 vs. MNK: 26.60 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.90
MNK's P/B is ranked higher than
60% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. MNK: 2.90 )
Ranked among companies with meaningful P/B only.
MNK' s 10-Year P/B Range
Min: 1   Max: 3.59
Current: 2.9

1
3.59
P/S 3.70
MNK's P/S is ranked lower than
57% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNK: 3.70 )
Ranked among companies with meaningful P/S only.
MNK' s 10-Year P/S Range
Min: 1.11   Max: 3.71
Current: 3.7

1.11
3.71
PFCF 29.00
MNK's PFCF is ranked higher than
79% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 491.77 vs. MNK: 29.00 )
Ranked among companies with meaningful PFCF only.
MNK' s 10-Year PFCF Range
Min: 18.94   Max: 45.83
Current: 29

18.94
45.83
POCF 21.16
MNK's POCF is ranked higher than
78% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.87 vs. MNK: 21.16 )
Ranked among companies with meaningful POCF only.
MNK' s 10-Year POCF Range
Min: 12.38   Max: 45.83
Current: 21.16

12.38
45.83
Current Ratio 2.86
MNK's Current Ratio is ranked higher than
71% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. MNK: 2.86 )
Ranked among companies with meaningful Current Ratio only.
MNK' s 10-Year Current Ratio Range
Min: 2.29   Max: 2.86
Current: 2.86

2.29
2.86
Quick Ratio 2.41
MNK's Quick Ratio is ranked higher than
73% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. MNK: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
MNK' s 10-Year Quick Ratio Range
Min: 1.5   Max: 2.41
Current: 2.41

1.5
2.41
Days Inventory 88.95
MNK's Days Inventory is ranked higher than
73% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 151.00 vs. MNK: 88.95 )
Ranked among companies with meaningful Days Inventory only.
MNK' s 10-Year Days Inventory Range
Min: 62.36   Max: 109.13
Current: 88.95

62.36
109.13
Days Sales Outstanding 63.06
MNK's Days Sales Outstanding is ranked higher than
70% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.78 vs. MNK: 63.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNK' s 10-Year Days Sales Outstanding Range
Min: 66.36   Max: 78.39
Current: 63.06

66.36
78.39

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.90
MNK's Price/Median PS Value is ranked lower than
55% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. MNK: 1.90 )
Ranked among companies with meaningful Price/Median PS Value only.
MNK' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 1.86
Current: 1.9

0.61
1.86
Earnings Yield (Greenblatt) -0.80
MNK's Earnings Yield (Greenblatt) is ranked lower than
63% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. MNK: -0.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
MNK' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.8   Max: 5
Current: -0.8

-0.8
5

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 3,755 4,037 4,352
EPS($) 7.46 4.75 9.90
EPS without NRI($) 7.46 4.75 9.90

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:MCD.Germany,
Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and diagnostic imaging agents. Its specialty pharmaceutical products are sold to wholesalers and retail drugstore chains. The Company's Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The Company's products include Intrathecal Product used in the management of cerebral or spinal spasticity. The Company's nonsteroidal anti-inflammatory drug (NSAID) portfolio helps address the signs and symptoms of painful condition. PENNSAID, is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). The Opioid products include EXALGO. It is an Extended-Release Tablets indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. The Central Nervous Systems' products include Anafranil, indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The Global Medical Imaging products includes Optisuite, Optibolus Bolus Shaping Software, Ready-Box, Ultra-Technekow DTE Generator, Octreoscan, and Technescan MAG3.
» More Articles for MNK

Headlines

Articles On GuruFocus.com
Only Buy Luxury At A Deep Discount Apr 01 2015 
Mallinckrodt Has Brighter Days Going Ahead Mar 10 2015 
Paulson Bets Again On Mallinckrodt Aug 07 2014 
Dumb Investment of the Week: Mallinckrodt PLC Jul 17 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Can Malllinckrodt Keep on Crushing Expectations? Mar 19 2014 
Should You Buy Actavis? Mar 18 2014 
Weekly 3-Year Low Highlight: EW, NUAN, MNK, CROX, IRDM Nov 03 2013 

More From Other Websites
Mallinckrodt To Present At Goldman Sachs 36th Annual Healthcare Conference May 27 2015
Mallinckrodt To Present At Goldman Sachs 36th Annual Healthcare Conference May 27 2015
Mallinckrodt Extends Deadline For 2015 Research Fellowship Program May 26 2015
Mallinckrodt Extends Deadline For 2015 Research Fellowship Program May 26 2015
Mallinckrodt: Ofirmev, Acthar And A Nearby Buy Point May 20 2015
Mallinckrodt plc announces €45m Investment in Ireland May 20 2015
Mallinckrodt, Taiwan Semiconductor Near Buy Points May 19 2015
John Paulson Buys Actavis, AIG, Valeant, Sells Equinix, Alibaba May 16 2015
The FDA's Authority Challenged By Mallinckrodt May 15 2015
[$$] Can FDA Reclassify Generic Drugs? May 14 2015
MALLINCKRODT PLC Financials May 13 2015
DEPO: Selloff Creates Great Opportunity In Depomed May 13 2015
Many Leaders Forming Bases As Market Correction Takes Hold May 07 2015
Leading Stock Mallinckrodt Delivers Strong Results As Base Forms May 06 2015
Mallinckrodt (MNK) Earnings Report: Q2 2015 Conference Call Transcript May 06 2015
Company News for May 06, 2015 - Corporate Summary May 06 2015
Mylan Q1 Mixed; Abiomed, Mallinckrodt, Zoetis Beat May 05 2015
Trending Swing Trades On the Verge of Triggering May 05 2015
Mallinckrodt Tops Q2 Earnings & Revenues on Acquisitions - Analyst Blog May 05 2015
Estée Lauder gains on earnings; Netflix gets buy rating May 05 2015
Abiomed, Mallinckrodt, Zoetis Beat Q1 Estimates May 05 2015
Mallinckrodt Plc Earnings Call scheduled for 8:30 am ET today May 05 2015
Mallinckrodt (MNK) Beats on Q2 Earnings & Revenues - Tale of the Tape May 05 2015
Mallinckrodt Profit Surges After Ikaria Acquisition May 05 2015
Mallinckrodt plc Reports Fiscal 2015 Second Quarter Financial Results; Raises Full Year 2015... May 05 2015
MALLINCKRODT PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 05 2015
Mallinckrodt beats Street 2Q forecasts May 05 2015
Mallinckrodt To Present At Bank Of America Merrill Lynch 2015 Health Care Conference May 04 2015
Mallinckrodt To Present At Deutsche Bank Healthcare Conference Apr 22 2015
Mallinckrodt Completes Acquisition Of Ikaria Apr 16 2015
Mallinckrodt Statement On Agreement To Settle Questcor Shareholder Lawsuit Apr 13 2015
Mallinckrodt plc to Report Second Quarter Fiscal 2015 Results on May 5, 2015 Apr 07 2015
Mallinckrodt Launches Notes Offering Apr 06 2015
Mallinckrodt Receives Favorable Decision in Ofirmev (Acetaminophen) Injection Patent Case Mar 24 2015
Mallinckrodt Supports Safe Home Disposal Of Unused Medications Mar 10 2015
Mallinckrodt to Present at Barclays Conference March 11 Mar 04 2015
Mallinckrodt beats 1Q profit forecasts Feb 03 2015
Mallinckrodt plc Announces Share Repurchase Program Jan 23 2015
Mallinckrodt Builds Leadership To Support Continued Growth Jan 07 2015
Mallinckrodt plc to Report First Quarter Fiscal 2015 Results on February 3, 2015 Jan 05 2015
Mallinckrodt to Present at J.P. Morgan Healthcare Conference January 12 Dec 22 2014
Mallinckrodt Responds to Court Decision Nov 25 2014
Information About Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) Nov 24 2014
Mallinckrodt Responds to FDA Reclassification Of Methylphenidate ER Nov 24 2014
Wal-Mart and Viacom are big market movers Nov 13 2014
Mallinckrodt plc to Report Fourth Quarter and Full-Year Fiscal 2014 Results on November 19, 2014 Oct 20 2014
Mallinckrodt shares rise on earnings outlook Oct 14 2014
Two trades push high-yield week to US$4.133bn Jul 30 2014
More U.S. companies doing deals to avoid U.S. taxes - Congress study Jul 07 2014
Mallinckrodt to buy Questcor Pharma for $5.6 bn Apr 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK